Ernexa Therapeutics Inc.
No SEC Form 4 filings for $ERNA in the last 30 days.
Ernexa Therapeutics (Nasdaq: ERNA) said it has completed process development for ERNA-101 and transitioned toward GMP manufacturing, while technology transfer activities are underway. The company expects to file an IND for ERNA-101 in Q3 2026, enabling a planned first-in-human study.
CAMBRIDGE, Mass., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Ernexa Therapeutics ( NASDAQ:ERNA ) , an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will present at Cell 2025, Oxford Global's premier event, being held ...
The Company's operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1 study in platinum-resistant ovarian cancer ( PROC ) , ...
